INS and Hypoglycemia: When possibilities for T2DM control with oral antidiabetic medication and lifestyle changes have been exhausted the ADA reference indicates that patients with T2DM may benefit additionally from insulin therapy, where long-acting basal analogs demonstrate greater reduction in the risk of hypoglycemia compared to NPH insulin [8••].